EMA Accepts Valneva's Chikungunya Vaccine Marketing Authorization Application for Accelerated AssessmentGlobeNewsWire • 11/27/23
Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including Planned Changes to its Future Board of DirectorsGlobeNewsWire • 11/15/23
Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chikungunya Vaccine CandidateGlobeNewsWire • 11/13/23
Valneva Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ®GlobeNewsWire • 11/10/23
Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 11/09/23
Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare ConferenceGlobeNewsWire • 11/07/23
Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated AssessmentGlobeNewsWire • 10/25/23
Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 MillionGlobeNewsWire • 09/25/23
Valneva Reports Half Year 2023 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 09/21/23
Pfizer, Valneva announce 'positive' results for Lyme disease vaccine candidate booster shotReuters • 09/07/23
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine CandidateGlobeNewsWire • 09/07/23
Valneva to Participate in Investor Conferences in the United States and Europe in September 2023GlobeNewsWire • 08/31/23
Health Canada Accepts Valneva's Chikungunya Vaccine License Application for ReviewGlobeNewsWire • 08/29/23
Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine CandidateGlobeNewsWire • 08/28/23
NorthX Biologics Welcomes Dr Janet Hoogstraate as New CEO Following Merger with Valneva Clinical Trials Manufacturing UnitGlobeNewsWire • 08/23/23
Valneva Announces PDUFA Date Extension for Chikungunya Virus Vaccine CandidateGlobeNewsWire • 08/14/23